Member Info for Hurst10

Https://www.biospace.com/article/roche-alnylam-ink-potential-2-8b-rnai-partnership-for-hypertension/

You mean: long Avacta - short diary futures ?

Regular prints at the 102.70ish level

It is a matter of, can one afford to hold on and buy more on weak days and take profits on the right days.

Profit taking because you want to and not because you have to.

Right now you have the easiest 50% you can make in the market, with an avalanche of RNS’ around the corner.

Note one does not have to be rude to make your point!

This time just printing 10/ buys till the market steps back and you have 10-20 and testing the buyer.

He will then test the market and start buying in 100/ and see what is left.

A couple of size buy orders and you have 30/ offered.

Once lifted and you know it is not stopping here and then RNS.

New price range coming up

Https://www.biospace.com/article/regenerative-medicine-challenges-hinder-their-development-and-use-gao/

+

The watchdog group also recommended that federal agencies could help by supporting public-private partnerships that can share costs for manufacturing facilities.

Lots of Corporate news in the sector:Roviant Sciences(ROIV) in discussions to sell its experimental drug RVT-3101 for treating Bowel diseases to Roche, could be worth over $7bill.

Eli Lilly to aquire Versanis, $2bill.

Caribou stock offering $125mill

Frequency Therapeutics merger with Korro Bio

Sagimet(SGMT) priced its upsized IPO at $16.00

and then with Avacta we could have a RNS on Monday with Cohort update and throw in a License agreement as well.

and more to come.

New York offices ? perhaps close to Wall street

US buyers are laughing as they are picking up stock 30% below next week’s level and off course RNS on Cohort etc

Fundraise is wishful thinking from the usual gang, meanwhile back in the real world, offer price being lifted again and again.

I do like Friday’s, plenty of upside. Let us see closing price!

Size buyers stepping in, early hours, could be a lively afternoon.

Bicycle Therapeutics Announces Proposed $200 Million Public Offering of American Depositary Shares and Non-Voting Ordinary Shares.

Out late afternoon, Corporate Biotech picking up again.

Following the acquisitions in the Diagnostic division and closing the Cambridge office, interesting to note the comment on page 45 in Avacta’s business review, ref. the diagnostic division “ benefiting from synergies across the division”!

Believed to be the first FDA IND clearance of an allogeneic dual CAR-T therapy targeting CD19 and CD20

SAN DIEGO, July 5, 2023 /PRNewswire/ -- Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage cell and gene therapy company advancing a new class of treatments for patients with cancer and rare diseases, today announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for P-CD19CD20-ALLO1, the Company's first allogeneic dual CAR-T cell product candidate, which targets both CD19 and CD20 antigens for the treatment of relapsed or refractory B-cell malignancies and is being developed in partnership with Roche.

More funds to Novartis:

June 30 (Reuters) - Bausch + Lomb Corp (BLCO.TO) will purchase a dry-eye drug from Swiss pharma company Novartis (NOVN.S) for $1.75 billion, the Wall Street Journal reported on Friday, as the contact lens maker seeks to capitalise on a growing market for the disease's treatment.

Ref Diagnostic division, on page 45 in the presentation,

“ our immediate focus now is on growing the acquired businesses and benefiting from synergies across the division”.

Synergies = Cost-savings!

When the likes of Conifer increases their holding, you have their US investors paying attention and the second half of 2023 could very much be for overseas shareholders.

Meanwhile size buyer stepping in

It has already been agreed, could be one of the Biotech IPO’s of the year, shareholder base changing !

Very clear, they are in discussion and one would expect an announcement soon.

FDA Approves First-Line Enzalutamide/Talazoparib Combo in Prostate Cancer.

Ref AVA3996 a novel pre|CISION medicine

Did the Ceo not mentioned that the company was looking for the right forum to produce the latest data and that would obviously indicate that the next Cohort level has commenced ?